Results 271 to 280 of about 103,365 (348)

Effectiveness and adherence in a tirzepatide‐supported digital weight‐loss programme in Australia: A real‐world observational study

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims Obesity is a growing global health crisis; pharmacotherapies such as tirzepatide combined with multidisciplinary lifestyle support have shown promise but real‐world evidence in digital weight‐loss services (DWLSs) is limited. This retrospective study evaluated 6‐ and 12‐month weight loss, adherence and predictors of outcomes in an ...
Louis Talay, Jason Hom, Tamara Scott, Neera Ahuja   +3 more
wiley   +1 more source

Rate of Age-Related Macular Degeneration in Patients Prescribed Glucagon-Like Peptide-1 Receptor Agonists or Other Weight Loss Therapies. [PDF]

Ophthalmol Retina
Myers WK, Heath G, Rohrer B.
europepmc   +1 more source

Diabetic kidney disease, biomarkers, and finerenone

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Diabetic kidney disease (DKD), the leading cause of kidney failure worldwide, is associated with an increased risk of cardiovascular disease (CVD). A complex pathobiology involving hemodynamic, metabolic, and immune dysregulation promotes inflammatory and fibrotic pathways that contribute to kidney disease progression and CVD in individuals ...
Ashish Verma, Ashish Upadhyay
wiley   +1 more source

Glucagon-like Peptide-1 Receptor Agonists in Heart Failure: Mechanisms, Evidence and Identifying Optimal Candidates. [PDF]

Card Fail Rev
Abdelhamid M, Abdrabou MM, Faris E, El Kafas S, Hosny M, Hassan A.   +5 more
europepmc   +1 more source

Changes in how people living with obesity perceive weight‐related discussions with their healthcare professional: Results from the cross‐sectional online ACTION‐DK 2022 and 2024 studies

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims This study investigated changes in how people living with obesity (PwO) perceive weight‐related discussions with healthcare professionals (HCPs) in Denmark from 2022 to 2024, a period marked by shifts in obesity treatment options as well as the broader understanding of obesity.
Mette Bøgelund, Amanda F. Rasmussen, Pernille Andreassen, Per Nielsen, Signe Stensen, Jens M. Bruun   +5 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist in large vessel occlusion treated by reperfusion therapy-a phase 2 randomized trial. [PDF]

Nat Commun
Wang H, Ko H, Leung TW, Huang J, Sai J, Liang Y, Li H, Zhang J, Cao Q, Zang W, Li Y, Ma SH, Lui WT, Choi J, Chan C, Wong J, Kwok AJ, Ma K, Fan F, Chan A, Ip V, Leung H, Soo Y, Wong KT, Lai B, Chu CM, Leung HS, Hui A, Cheung T, Abrigo J, Li SH, Chan L, Yeung J, Pan S, Yip T, Lui LT, Hung T, Tsang SF, Leng X, Lam B, Mok VCT, Chan RHM, Nguyen TN, Hu W, Che F, Ip BY.   +45 more
europepmc   +1 more source

Effect of empagliflozin on urinary albumin excretion and hypoxic biomarkers in early diabetic kidney disease: A randomised double‐blind, placebo‐controlled trial

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims The precise mechanism of sodium glucose co‐transporter 2 (SGLT2) inhibitor on reno‐protective effect has been still unclear. In this study, we hypothesised that SGLT2 inhibitor prevents diabetic kidney disease via reduction of hypoxia‐induced factors.
Hisashi Makino, Masato Kasahara, Ryuzo Takashima, Shu Kasama, Naoki Ozu, Hyohun Park, Qingxing Chen, Kazuhiko Tsuruya, Mayu Tochiya, Yoko Omura‐Ohata, Tamiko Tamanaha, Michio Noguchi, Takeshi Aiba, Fumiki Yoshihara, Kiminori Hosoda   +14 more
wiley   +1 more source

Glucagon-like peptide-1 receptor agonist and respiratory complications after endoscopy: A Japanese nationwide cohort study. [PDF]

Diabetes Obes Metab
Hisada H, Ikeuchi K, Tsuji Y, Yamamichi N, Kakushima N, Okushin K, Yakabi S, Takeuchi C, Ohki D, Mizutani H, Miura Y, Kubota D, Tsutsumi T, Fujishiro M.   +13 more
europepmc   +1 more source

Risk of acute pancreatitis with DPP‐4 inhibitors versus SGLT2 inhibitors in medication‐naïve individuals with diabetes: A target trial emulation

Diabetes, Obesity and Metabolism, EarlyView.
Abstract Aims We investigated whether dipeptidyl peptidase‐4 inhibitor (DPP‐4i) use was associated with a higher risk of acute pancreatitis compared with sodium–glucose cotransporter 2 inhibitor (SGLT2i) use in antidiabetic medication‐naïve individuals.
Takashi Tatewaki, Akira Okada, Yuya Kimura, Hideo Yasunaga   +3 more
wiley   +1 more source

The Analysis Study of Effects of Glucagon-Like Peptide-1 Receptor to Reduce Adverse Cardiovascular Events in Patients with Type 2 Diabetes Mellitus: A Comprehensive Systematic Review

Radian Tommy Firmansyah, Lydia Nur Amalia   +1 more
openalex   +2 more sources